JP2014525465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014525465A5 JP2014525465A5 JP2014528678A JP2014528678A JP2014525465A5 JP 2014525465 A5 JP2014525465 A5 JP 2014525465A5 JP 2014528678 A JP2014528678 A JP 2014528678A JP 2014528678 A JP2014528678 A JP 2014528678A JP 2014525465 A5 JP2014525465 A5 JP 2014525465A5
- Authority
- JP
- Japan
- Prior art keywords
- aromatase inhibitor
- treatment
- entinostat
- use according
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003886 aromatase inhibitor Substances 0.000 claims 50
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 47
- 229950005837 entinostat Drugs 0.000 claims 37
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 37
- 230000020015 peptidyl-lysine deacetylation Effects 0.000 claims 27
- 238000002648 combination therapy Methods 0.000 claims 13
- 206010006187 Breast cancer Diseases 0.000 claims 9
- 208000026310 Breast neoplasm Diseases 0.000 claims 9
- 239000002552 dosage form Substances 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- 238000002560 therapeutic procedure Methods 0.000 claims 7
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 6
- 229960000255 exemestane Drugs 0.000 claims 6
- 229960002932 anastrozole Drugs 0.000 claims 4
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 4
- 230000000977 initiatory effect Effects 0.000 claims 4
- 229960003881 letrozole Drugs 0.000 claims 4
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical group C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 4
- 229940046844 aromatase inhibitors Drugs 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 claims 2
- 230000003637 steroidlike Effects 0.000 claims 2
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 claims 1
- 229960003649 eribulin Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- 238000002625 monoclonal antibody therapy Methods 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 208000037821 progressive disease Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 238000011476 stem cell transplantation Methods 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530873P | 2011-09-02 | 2011-09-02 | |
| US61/530,873 | 2011-09-02 | ||
| US201161532534P | 2011-09-08 | 2011-09-08 | |
| US61/532,534 | 2011-09-08 | ||
| US201161628999P | 2011-11-12 | 2011-11-12 | |
| US61/628,999 | 2011-11-12 | ||
| US201161568110P | 2011-12-07 | 2011-12-07 | |
| US61/568,110 | 2011-12-07 | ||
| PCT/US2012/053551 WO2013033656A1 (en) | 2011-09-02 | 2012-08-31 | Methods for the treatment of breast cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017084847A Division JP2017149761A (ja) | 2011-09-02 | 2017-04-21 | 乳癌の処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014525465A JP2014525465A (ja) | 2014-09-29 |
| JP2014525465A5 true JP2014525465A5 (enExample) | 2015-11-05 |
| JP6195384B2 JP6195384B2 (ja) | 2017-09-13 |
Family
ID=47756940
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014528678A Active JP6195384B2 (ja) | 2011-09-02 | 2012-08-31 | 乳癌の処置方法 |
| JP2017084847A Pending JP2017149761A (ja) | 2011-09-02 | 2017-04-21 | 乳癌の処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017084847A Pending JP2017149761A (ja) | 2011-09-02 | 2017-04-21 | 乳癌の処置方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10226472B2 (enExample) |
| EP (2) | EP3381454A1 (enExample) |
| JP (2) | JP6195384B2 (enExample) |
| KR (1) | KR101956861B1 (enExample) |
| CN (3) | CN103906837A (enExample) |
| AU (2) | AU2012301616B2 (enExample) |
| BR (1) | BR112014005080A2 (enExample) |
| CA (1) | CA2847348A1 (enExample) |
| EA (1) | EA201201474A1 (enExample) |
| ES (1) | ES2663407T3 (enExample) |
| GE (1) | GEP201706612B (enExample) |
| HK (1) | HK1254859A1 (enExample) |
| MX (1) | MX358254B (enExample) |
| UA (6) | UA124240U (enExample) |
| WO (1) | WO2013033656A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA124240U (uk) | 2011-09-02 | 2018-03-26 | Общєство С Огранічєной Отвєтствєностью "Новамєдіка" | Спосіб вибору пацієнта для подальшої терапії er-позитивного раку молочної залози |
| KR102337598B1 (ko) * | 2013-05-03 | 2021-12-10 | 신닥스 파마슈티컬스, 인크. | 암 치료 방법 |
| US20180104232A1 (en) * | 2015-03-12 | 2018-04-19 | The University Of Chicago | Methods for determining prognosis for breast cancer patients |
| WO2017041043A1 (en) * | 2015-09-02 | 2017-03-09 | Syndax Pharmaceuticals, Inc. | Selection of patients for combination therapy |
| JP7373991B2 (ja) | 2016-07-15 | 2023-11-06 | ビラクタ セラピューティクス，インク． | 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤 |
| EP3487492A4 (en) * | 2016-07-20 | 2020-03-11 | Eisai R&D Management Co., Ltd. | USE OF ERIBULIN AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER |
| EP3624848A1 (en) | 2017-05-19 | 2020-03-25 | Syndax Pharmaceuticals, Inc. | Combination therapies |
| AU2019266231B2 (en) | 2018-05-07 | 2025-08-21 | Syndax Pharmaceuticals, Inc. | Selection of patients for combination therapy |
| KR102212699B1 (ko) | 2019-08-12 | 2021-02-05 | 한국원자력의학원 | 유방암 예방 또는 치료용 조성물 |
| US12377711B2 (en) | 2020-08-20 | 2025-08-05 | Denso International America, Inc. | Vehicle feature control systems and methods based on smoking |
| US11636870B2 (en) | 2020-08-20 | 2023-04-25 | Denso International America, Inc. | Smoking cessation systems and methods |
| US12017506B2 (en) | 2020-08-20 | 2024-06-25 | Denso International America, Inc. | Passenger cabin air control systems and methods |
| US11760169B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Particulate control systems and methods for olfaction sensors |
| US12251991B2 (en) | 2020-08-20 | 2025-03-18 | Denso International America, Inc. | Humidity control for olfaction sensors |
| US11813926B2 (en) | 2020-08-20 | 2023-11-14 | Denso International America, Inc. | Binding agent and olfaction sensor |
| US11881093B2 (en) | 2020-08-20 | 2024-01-23 | Denso International America, Inc. | Systems and methods for identifying smoking in vehicles |
| US12269315B2 (en) | 2020-08-20 | 2025-04-08 | Denso International America, Inc. | Systems and methods for measuring and managing odor brought into rental vehicles |
| US11760170B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Olfaction sensor preservation systems and methods |
| US11828210B2 (en) | 2020-08-20 | 2023-11-28 | Denso International America, Inc. | Diagnostic systems and methods of vehicles using olfaction |
| US11932080B2 (en) | 2020-08-20 | 2024-03-19 | Denso International America, Inc. | Diagnostic and recirculation control systems and methods |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US20100092992A1 (en) * | 2006-08-17 | 2010-04-15 | Peter Hornbeck | Lysine acetylation sites |
| WO2008154382A1 (en) | 2007-06-06 | 2008-12-18 | University Of Maryland, Baltimore | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| CA2726734C (en) * | 2007-06-06 | 2014-10-07 | University Of Maryland, Baltimore | Hdac inhibitor ms-275 and aromatase inhibitors for the treatment of cancer |
| WO2009067500A1 (en) * | 2007-11-19 | 2009-05-28 | Syndax Pharmaceuticals, Inc. | Administration of an inhibitor of hdac |
| CA2825969A1 (en) | 2011-02-02 | 2012-08-09 | Genentech, Inc. | Dosing for treatment with anti-egfl7 antibodies |
| AU2012250924B2 (en) | 2011-05-02 | 2017-05-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| UA124240U (uk) | 2011-09-02 | 2018-03-26 | Общєство С Огранічєной Отвєтствєностью "Новамєдіка" | Спосіб вибору пацієнта для подальшої терапії er-позитивного раку молочної залози |
| CH706458B1 (fr) | 2012-04-30 | 2017-05-15 | Granit Tech Sa | Procédé de cimentation pour le stockage de déchets. |
-
2012
- 2012-08-31 UA UAU201711135U patent/UA124240U/uk unknown
- 2012-08-31 CN CN201280053368.3A patent/CN103906837A/zh active Pending
- 2012-08-31 AU AU2012301616A patent/AU2012301616B2/en not_active Ceased
- 2012-08-31 CA CA2847348A patent/CA2847348A1/en not_active Abandoned
- 2012-08-31 US US14/342,354 patent/US10226472B2/en active Active
- 2012-08-31 UA UAU201711132U patent/UA124238U/uk unknown
- 2012-08-31 EA EA201201474A patent/EA201201474A1/ru unknown
- 2012-08-31 WO PCT/US2012/053551 patent/WO2013033656A1/en not_active Ceased
- 2012-08-31 KR KR1020147008685A patent/KR101956861B1/ko active Active
- 2012-08-31 UA UAA201512370U patent/UA149007U/uk unknown
- 2012-08-31 UA UAA201213781U patent/UA123212U/uk unknown
- 2012-08-31 ES ES12827061.8T patent/ES2663407T3/es active Active
- 2012-08-31 CN CN202110805646.7A patent/CN114053284A/zh active Pending
- 2012-08-31 BR BR112014005080A patent/BR112014005080A2/pt not_active Application Discontinuation
- 2012-08-31 JP JP2014528678A patent/JP6195384B2/ja active Active
- 2012-08-31 CN CN201711383372.7A patent/CN107982270A/zh active Pending
- 2012-08-31 GE GEAP201212972A patent/GEP201706612B/en unknown
- 2012-08-31 EP EP18152916.5A patent/EP3381454A1/en not_active Withdrawn
- 2012-08-31 UA UAU201711136U patent/UA124241U/uk unknown
- 2012-08-31 EP EP12827061.8A patent/EP2751267B1/en not_active Revoked
- 2012-08-31 MX MX2014002515A patent/MX358254B/es active IP Right Grant
- 2012-08-31 UA UAU201711134U patent/UA124239U/uk unknown
-
2017
- 2017-04-21 JP JP2017084847A patent/JP2017149761A/ja active Pending
-
2018
- 2018-05-02 AU AU2018203059A patent/AU2018203059A1/en not_active Abandoned
- 2018-11-01 HK HK18113956.5A patent/HK1254859A1/zh unknown
-
2019
- 2019-01-15 US US16/248,443 patent/US20190343844A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Peng et al. | Aspirin alleviates pulmonary fibrosis through PI3K/AKT/mTOR-mediated autophagy pathway | |
| JP2019523295A5 (enExample) | ||
| Sun et al. | Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia | |
| RU2018103064A (ru) | Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| EA201792541A3 (ru) | Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени | |
| JP2014511383A5 (enExample) | ||
| PT2269603E (pt) | Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano | |
| JP2015526458A5 (enExample) | ||
| Yang et al. | A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma | |
| UA124238U (uk) | Спосіб лікування раку молочної залози | |
| AU2023210543B2 (en) | Uses of myostatin antagonists, combinations containing them and uses thereof | |
| Wang et al. | α-Lipoic acid alleviates myocardial injury and induces M2b macrophage polarization after myocardial infarction via HMGB1/NF-kB signaling pathway | |
| RU2014117510A (ru) | Лечение ревматоидного артрита | |
| JP2023527542A5 (enExample) | ||
| RU2721555C2 (ru) | Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций | |
| RU2016148441A (ru) | Способ лечения pr-положительного люминального а-типа рака молочной железы ингибитором pi3k пиктилисибом | |
| JP2025515092A5 (enExample) | ||
| Izumo et al. | Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia | |
| JP2023549849A5 (enExample) | ||
| JP2023548005A5 (enExample) | ||
| Wu et al. | Gabapentin alleviates myocardial ischemia–reperfusion injury by increasing the protein expression of GABAARδ | |
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| JP2018522881A5 (enExample) | ||
| EP3160469A2 (en) | Methods of managing conditioned fear with neurokinin receptor antagonists |